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TO THE EDITOR
Recently, our understanding of pso-
riasis has expanded from a superficial
skin disease to a systemic inflammatory
process that affects multiple organs.
It has been postulated that circulating
high levels of pro-inflammatory cyto-
kines may predispose psoriasis
patients to serious comorbid con-
ditions such as atherosclerosis, psoriatic
arthritis, obesity, and diabetes
(Davidovici et al., 2010). However, the
mechanistic link between increased
circulating cytokine levels and these
comorbid conditions remains to be
established.
IL-17A (IL-17) is known to be a
central cytokine in psoriasis patho-
genesis. We previously reported signi-
ficant clinical improvements in patients
treated with ixekizumab (anti-IL-17A
monoclonal antibody), which were
accompanied by a rapid reversal of
epidermal hyperplasia and dermal infil-
tration of leukocytes (Krueger et al.,
2012). It is known that the level of
IL-17 is elevated in the blood of psoria-
sis patients (Sua´rez-Farin˜as et al., 2012)
but the effects of IL-17 on circulating
leukocytes bearing IL-17 receptors are
not fully understood. Human mono-
cytes highly express both IL-17RA and
IL-17RC, and chemotraffic in response
to IL-17 (Shahrara et al., 2009), and the
activation and recruitment of effector
monocytes are known to have a role in
the pathobiology of a number of systemic
inflammatory diseases, including comor-
bidities associated with psoriasis, such as
atherosclerosis, metabolic regulation in
adipose tissue, and psoriatic arthritis. In
this study we explored the role of IL-17 in
regulating monocyte activities in culture
as well as its impact on systemic inflam-
mation in psoriasis patients treated with
ixekizumab.
First, genomic profiling was per-
formed on normal CD14þ monocytes
treated with IL-17A (200 ng ml1) for
24 hours in culture. Genes that
were induced included pro-inflam-
matory cytokines (41.5-fold, Po0.1),
chemokines, genes associated with
inflammatory response, and molecules
involved in cytokine signal transduction
(Supplementary Table S1a and b
online). We also observed upregulation
of chemokine receptors, which mediate
monocyte chemotaxis (Supplementary
Table S1c online), such as CXCR4 and
CCR2, as well as cell adhesion mole-
cules that mediate the rolling and dock-
ing of monocytes on vascular endo-
thelial cells, including integrin a4, integ-
rin b2, platelet/endothelial cell adhesion
molecule 1, and CD99, which are
known to be critical for plaque forma-
tion in atherosclerosis (Supplementary
Table S1d online). These findings were
confirmed with Ingenuity Pathway Ana-
lysis software, which identified signaling
pathways that were most significantly
affected in monocytes after IL-17
stimulation. The Ingenuity Pathway
Analysis system identified numerous
pathways associated with a pro-inflam-
matory response that were positively
enriched, such as IL-17 signaling,
IL-6/STAT3 signaling, as well as the
leukocyte transendothelial migration
pathway, which includes additional
cell adhesion molecules associated
with platelet accumulation in athero-
sclerosis (Figure 1).
Figure 1. Ingenuity pathway analysis (IPA) software was used to identify altered gene expression in proinflammatory signaling pathways. (a–c) Left panels:
transcriptional changes in monocytes treated with IL-17 (200 ng ml 1) for 24 hours vs. control. (d–f) Right panels: transcriptional changes in the blood
of psoriasis patients after ixekizumab treatment (150 mg week 2 vs. baseline). Gene expression networks that are displayed include (a, d) the IL-17 signaling
pathway, (b, e) the IL-6/STAT3 signaling pathway, and (c, f) leukocyte transendothelial migration. Green designates inhibitions in gene expression; red
designates increases in gene expression. Applies to a–f.
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In the second part of our analysis,
we explored the impact of systemic
neutralization of IL-17 on the expression
of genes associated with both immune
activation and atherosclerosis in blood
samples from psoriasis patients treated
with ixekizumab (150mg at week 2 vs.
baseline). In comparison with the obser-
vations from the in vitro experiments,
systemic neutralization of IL-17 reduced
the expression of pro-inflammatory cyto-
kines, chemokines, and their receptors, as
well as genes involved in inflammatory
response. Notably, there was reduced
expression of cell surface molecules that
mediate leukocyte extravasation (Supple-
mentary Table S2c online), especially
those that mediate interactions of mono-
cytes with the vascular endothelium,
including matrix metalloproteinases, small
GTPase Cdc42, and integrins a4 and b1
(Supplementary Table S2c and d online).
Again, this blood-derived transcriptome
was overlapped with the Ingenuity Path-
way Analysis system, and in comparison
with the pathway changes we observed in
cultured monocytes, IL-17 signaling, IL-6/
STAT3 signaling, and leukocyte transen-
dothelial migration were significantly
repressed for nearly all gene members
after ixekizumab treatment (Figure 1).
To further explore the role of IL-17
in systemic inflammation in psoriasis
patient blood, we employed gene set
enrichment analysis. In patients treated
with ixekizumab compared with base-
line, there was broad suppression
of genes that belonged to pathways
that regulate inflammatory responses,
leukocyte transendothelial migration,
monocyte activities, and blood coagula-
tion each with a normalized enrich-
ment scoreo 1.4 (Supplementary
Figure S1 online). In comparison, these
same pathways were broadly upregu-
lated in the blood-derived transcriptome
of psoriasis patients compared with
healthy volunteers with a normalized
enrichment score of 4þ1.7 for each
gene set (Supplementary Figure S1
online). In addition, gene set enrichment
analysis showed significant suppression
of atherosclerosis signaling in the blood
transcriptome of psoriasis patients after
ixekizumab treatment (Po0.05, false
discovery rate qo0.1) with a normal-
ized enrichment score of 1.5 (Supple-
mentary Figure S2 online). Among the
most suppressed genes were ALOX5AP
(1.4-fold decrease, Po103) and
ALOX5, which have been implicated
in the inflammation of the arterial wall
and have been associated with increa-
sed risk for atherosclerosis (Back, 2009).
The expression of thrombospondin-1,
which is involved in the formation of
atherosclerotic lesions (Moura et al.,
2008), was decreased by 1.56-fold
(Po0.05), and genes related to athero-
sclerosis disease risks and platelet
aggregation (e.g., F2RL2) were also
suppressed.
Cardiovascular disease is one of the
most prevalent comorbidities associated
with psoriasis (Mehta et al., 2010) and
contributes substantially to the morbidity
and mortality rates in psoriatic patients
(Pietrzak et al., 2013). Recent studies have
indicated that IL-17 may be associated
with the development of cardiovascular
disease and atherosclerosis (Ding et al.,
2011; Madhur et al., 2011). In the apoE-
deficient mouse model, blockade of IL-17
effectively reduced atherosclerosis in
mice (Smith et al., 2010). Furthermore,
the monocyte-macrophage has an impor-
tant role in the development of athero-
sclerosis.
Using monocytes from healthy indivi-
duals, we generated a baseline response
of monocytes to IL-17. Conceivably,
monocytes from psoriasis patients may
behave differently in vitro, as they
are already exposed to high levels of
IL-17 in circulation (Sua´rez-Farin˜as
et al., 2012) and are known to over-
produce cytokines (e.g., IL-1b, IL-6, IL-8
and tumor necrosis factor) (Mizutani
et al., 1997; Okubo and Koga, 1998).
Our data showed that IL-17 promotes
an inflammatory state in blood mono-
cytes. Remarkably, many of the induced
genes are associated with cardiovas-
cular disease risk, including IL-8,
CXCL1, CXCL5, and IL-1a/b (Holm
et al., 2003; Rousselle et al., 2013). In
addition, CCR2/CCL2 and CXCR4/SDF-1
are receptor/ligand pairs that have
been considered as therapeutic targets
for atherosclerosis (Boring et al., 1998;
Wen et al., 2012); IL-17 may also pro-
mote monocyte adhesion by inducing
molecules (e.g., ICAM1, integrin a4,
platelet/endothelial cell adhesion mole-
cule 1, CD99) that are essential for tran-
sient interactions between leukocytes
and the blood vessel wall (Woollard
and Geissmann, 2010).
Analysis of the blood transcriptome in
psoriasis patients receiving ixekizumab
revealed decreased expression of che-
mokines and receptors that are asso-
ciated with atheroslerosis disease risk,
including CXCR4 and CXCR6. Other
factors, such as GM-CSF, trigger the
differentiation of monocytes into subpo-
pulations of macrophages at athero-
sclerotic lesions (Di Gregoli and
Johnson, 2012). ALOX5AP is required
for leukotriene synthesis, and inhibitors
of the 5-lipoxygenase pathways are
being tested for cardiovascular disease
in clinical trials (Back, 2009).
As CD14þ monocytes represent only
about 10% of all blood leukocytes in
humans, decreased inflammation in the
ixekizumab-treated blood transcriptome
may reflect changes in the inflammatory
states of other leukocyte populations,
which warrants further investigation.
Past studies in rheumatoid arthritis
have shown that systemic immune inhi-
bitors can prevent atherosclerosis
and lower the risk for cardiovascular
disease (Pietrzak et al., 2013). For ins-
tance, tumor necrosis factor blockers,
including infliximab, etanercept, and
adalimumab, have been found to delay
the first cardiovascular event and reduce
the incidence of myocardial infarction
and cardiovascular-related mortality
in rheumatoid arthritis patients
(Jacobsson et al., 2005; Dixon et al.,
2007; Kerekes et al., 2009). In psoriasis
patients, antitumor necrosis factor
treatment was associated with
decreased levels of serum inflamma-
tory markers related to cardiovascular
risks such as C-reactive protein, homo-
cysteine, and other proinflammatory cyto-
kines (Mastroianni et al., 2005; Strober
et al., 2008; Yost and Gudjonsson, 2009).
However, the impact of systemic anti-
inflammatory therapies on cardiovascular
disease outcomes has yet to be esta-
blished, and other retrospective studies
have reported inconsistent findings. A
recent Danish study using nationwide
prospectively recorded registries showed
significantly decreased rates of cardio-
vascular disease events in patients
treated with biological agents and metho-
trexate compared with those treated with
other anti-psoriatic therapies (Ahlehoff
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et al., 2013). In another report, the protec-
tive effects of systemic anti-inflammatory
treatment on myocardial infarction were
only found in younger patients but not in
the general population (Abuabara et al.,
2011). In addition, increased occurrence
of cardiovascular disease events has been
reported in randomized controlled clinical
trials of anti-IL-12/23 therapies (Tzellos
et al., 2013), but a meta-analysis of
long-term (5 years) safety shows no
increased risk for cardiovascular disease
events during ustekinumab treatment
(Papp et al., 2013). Therefore, prospec-
tive studies with accepted surrogate end
points or adverse cardiovascular event
rates are needed to determine the impact
of anti-IL-17 treatment for cardiovascular
disease.
Overall, our data suggest that IL-17
has an important role in establishing
systemic inflammation in psoriasis and
may do so via its effects on monocytes.
Our findings will be important for
understanding how neutralization of
IL-17 might attenuate systemic inflam-
mation and impact psoriasis-associated
comorbidities such as cardiovascular
disease and atherosclerosis.
The clinical trial of ixekizumab in
patients with psoriasis was conducted
according to the principles expressed in
the Declaration of Helsinki, and written
informed consent was obtained from all
subjects, who provided samples in this
study.
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